

Drug persistence and incidence of active tuberculosis of tumor necrosis factor-alpha inhibitors versus tocilizumab as the first-line biological treatment in patients with rheumatoid arthritis: a nationwide population-based retrospective cohort analysis

Min Wook So^{1,2}, A-Ran Kim^{1,3,4}, Seung-Geun Lee^{1,3,4}

¹ Department of Internal Medicine, Pusan National University School of Medicine, Yangsan, Republic of Korea


² Division of Rheumatology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea

³ Division of Rheumatology, Department of Internal Medicine, Pusan National University Hospital, Busan, Republic of Korea

⁴ Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea

Correspondence to Seung-Geun Lee, Division of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, 179 Gudeok-Ro, Seo-Gu, 49241, Busan, South Korea, E-mail: sglee@pusan.ac.kr, Fax: +82-51-241-7580, Tel: +82-51-240-7580

ORCID ID: Min Wook So, 0000-0001-5027-0410; Aran Kim, 0000-0002-9165-8996; Seung-Geun Lee, 0000-0002-5205-3978.



Adalimumab	1413	1045	770	593	500	393	294	234	154	104	63	32	2
Etanercept	1100	793	636	495	398	305	238	170	126	89	65	37	3
Golimumab	920	675	524	415	332	266	186	144	108	78	45	21	4
Infliximab	769	591	442	370	314	257	214	182	142	110	80	46	6
Tocilizumab	1247	1015	882	796	725	608	449	355	266	202	128	62	9